Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Asian Stocks Up Over Fed’s Continued Dovish Tone, COVID-19 Vaccine Progress

Published 02/24/2021, 10:42 PM
Updated 02/24/2021, 10:44 PM
© Reuters.

By Gina Lee

Investing.com – Asia Pacific stocks were up Thursday morning, boosted by a bond selloff and reassurance from U.S. Federal Reserve Chairman Jerome Powell that interest rates would remain low.

Japan’s Nikkei 225 rose 1.66% by 10:38 PM ET (3:38 AM GMT) and South Korea’s KOSPI jumped 2.53%. In Australia, the ASX 200 gained 1%.

Hong Kong’s Hang Seng Index rose 2.11%. Financial secretary Paul Chan handed down the city’s budget on Wednesday, with eligible residents to receive HK$5,000 ($644.77) in digital coupons. Chan also raised the stamp duty for stock transactions to 0.13% from the previous 0.1%.

China’s Shanghai Composite gained 1.07% and the Shenzhen Component was up 0.78%.

Powell’s comments during a second day of testimony before Congress on Wednesday, helped calm fears that higher inflation rates could see the central bank tighten monetary policy.

He pointed out the long road ahead for the U.S. economic recovery and that signs of prices rising would not necessarily lead to persistently high inflation, telling the House Financial Services Committee, “Our policy is accommodative because unemployment is high and the labor market is far from maximum employment."

“The dovish influence from the Fed is going to continue to resonate over in Asia. That’s really good for emerging market assets when we’ve got a really good impulse from the Fed,” Axi chief global markets strategist Stephen Innes told Reuters.

On the COVID-19 vaccines front, results from an Israeli study published and peer-reviewed in the New England Journal of Medicine on Wednesday gave investors sentiment a boost. The study showed that two doses of the Pfizer Inc. (NYSE:PFE)/BioNTech SE (F:22UAy) COVID-19 vaccine cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The U.S. Food and Drug Administration also said on Wednesday that Johnson & Johnson's (NYSE:JNJ) one-dose COVID-19 vaccine appeared safe and effective in clinical trials, with emergency use approval potentially coming by the end of the week.

Investors are analyzing the market implications of a faster-than expected recovery, as “the combination of pent-up demand, with the stimulus checks on top of that, could lift inflation,” Barclays’ head of global inflation market strategy Michael Pond told Bloomberg.

However, investors will also have to analyze a new variant of the COVID-19 virus that is on the rise in New York City. The new variant, known as B.1.526, shares some similarities with the more transmissible variant discovered in South Africa and was first identified in November 2020. The NYC variant represented around 12% of all cases by mid-February, researchers at Columbia University Vagelos College of Physicians and Surgeons, said on Wednesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.